Ainos, Inc. (AIMD)
NASDAQ: AIMD · IEX Real-Time Price · USD
1.040
-0.010 (-0.94%)
At close: Apr 26, 2024, 4:00 PM
1.030
-0.010 (-0.97%)
After-hours: Apr 26, 2024, 4:54 PM EDT
Ainos Revenue
Revenue in the quarter ending December 31, 2023 was $-102.21K, a -95.88% decrease year-over-year.
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
46
Market Cap
6.19M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 0 | - | - |
| Dec 31, 2022 | 0 | - | - |
| Dec 31, 2021 | 594.56K | 578.00K | 3,489.71% |
| Dec 31, 2020 | 16.56K | 4.83K | 41.19% |
| Dec 31, 2019 | 11.73K | -65.99K | -84.91% |
| Dec 31, 2018 | 77.72K | -173.20K | -69.03% |
| Dec 31, 2017 | 250.93K | - | - |
| Dec 31, 2016 | 0 | - | - |
| Dec 31, 2015 | 0 | - | - |
| Dec 31, 2014 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Avinger | 7.65M |
| Assure Holdings | 3.57M |
| Xenetic Biosciences | 2.54M |
| Scorpius Holdings | 2.23M |
| Predictive Oncology | 1.78M |
| Mangoceuticals | 731.49K |
| Azitra | 686.00K |
AIMD News
- 7 weeks ago - Ainos Reports Full Year 2023 Financial Results - Accesswire
- 2 months ago - Ainos Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase II Trial of its VELDONA Formulation Against Mild COVID-19 Symptoms - Accesswire
- 3 months ago - Ainos Announces $1.75 Million Follow-On Funding - Accesswire
- 4 months ago - Ainos Regains Compliance with Nasdaq Minimum Bid Price Requirement - Accesswire
- 4 months ago - Ainos, Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-development Powered by AI Nose, Accelerating the Digitalization of Smell - Accesswire
- 4 months ago - Ainos, Inc. Announces Stock Consolidation - Accesswire
- 5 months ago - Ainos Announces Successful Manufacturing of VELDONA GMP Clinical Batch by Swiss Pharmaceutical - Accesswire
- 5 months ago - Ainos Announces Positive Data Reported from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA - Accesswire